HMPL-523

DRUG13 trials

Sponsors

Hutchison Medipharma Limited, Hutchmed

Conditions

Acute Myeloid LeukemiaAutoimmune DiseasesBlood Coagulation DisorderBlood Platelet DisorderHealthyHealthy SubjectHematologic DiseasesHematologic Malignancies

Early Phase 1

A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

CompletedNCT05318820

Hutchison Medipharma LimitedHealthy Subject

Start: 2022-06-01End: 2022-09-30Updated: 2023-04-25

Phase 1

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

CompletedNCT02105129

Hutchison Medipharma LimitedRheumatoid Arthritis (RA)

Start: 2014-05-31End: 2015-12-31Updated: 2016-04-28

A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies

Hutchison Medipharma LimitedHematologic Malignancies

Start: 2015-11-30End: 2021-03-31Target: 78Updated: 2020-09-11

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

CompletedNCT02857998

Hutchison Medipharma LimitedMature B-cell Neoplasms

Start: 2016-12-27End: 2021-09-30Updated: 2024-07-16

Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

TerminatedNCT03483948

Hutchison Medipharma LimitedAcute Myeloid Leukemia

Start: 2018-10-09End: 2019-09-09Updated: 2019-11-20

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

TerminatedNCT03779113

HutchmedNon Hodgkin Lymphoma

Start: 2019-09-26End: 2025-02-26Updated: 2026-02-18

The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients

CompletedNCT03951623

Hutchison Medipharma LimitedImmune Thrombocytopenia (ITP)

Start: 2019-08-12End: 2022-07-31Updated: 2024-07-16

HMPL-523 Food Effect and Proton Pump Inhibitor Study

CompletedNCT05571787

HutchmedRelapsed or Refractory Lymphoma

Start: 2022-07-13End: 2022-09-22Updated: 2023-02-23

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

CompletedNCT05720767

HutchmedRelapsed or Refractory Lymphoma

Start: 2022-11-04End: 2023-02-05Updated: 2023-03-01

Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects

CompletedNCT05781906

HutchmedImumune Thrombocytopenia(ITP) Human Mass Balance

Start: 2023-02-08End: 2023-12-06Updated: 2024-07-16

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

WithdrawnNCT06291415

HutchmedAutoimmune Diseases, Blood Coagulation Disorder, Blood Platelet Disorder +14

Start: 2024-04-02End: 2026-11-30Updated: 2025-09-16

Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets

CompletedNCT07348133

HutchmedHealthy

Start: 2025-12-11End: 2026-02-06Updated: 2026-02-12

Phase 3

Phase III Study on HMPL-523 for Treatment of ITP

CompletedNCT05029635

HutchmedPrimary Immune Thrombocytopenia (ITP)

Start: 2021-10-27End: 2025-09-18Updated: 2026-05-04

Related Papers

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood2025-11-03

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood2024-11-051 citations

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.

2024-07-013 citations

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.

2024-06-1418 citations

Abstract CT144: Safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma

Cancer Research2024-04-05

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.

2024-01-026 citations

Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.

2023-04-0414 citations

Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Adult Patients with Primary Immune Thrombocytopenia: A Randomized, Double-Blind and Placebo-Controlled Phase 1b Study

Blood2021-11-058 citations

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma

Blood2021-11-052 citations

A Phase 1 Study of HMPL-523, Highly Selective and Potent a Small Molecule Inhibitor of Spleen Tyrosine Kinase in Patients with Relapsed or Refractory Lymphoma

Blood2020-11-04

Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas

Blood2018-11-293 citations